Literature DB >> 11205092

How well are patients with atherosclerotic disease treated? Secondary prevention in primary care.

A Svilaas1, M Thoresen, J E Kristoffersen, J Hjartaaker, A Westheim.   

Abstract

OBJECTIVE: To examine changing trends in the field of secondary prevention of atherosclerotic disease in Norwegian general practice.
DESIGN: A multipractice survey of consecutive patients with atherosclerotic disease consulting general practitioners in 1994/95 compared with a similar survey in 1996/97.
SETTING: Primary health care.
SUBJECTS: 707 patients attending 31 general practitioners in 1994/95 and 1353 patients attending 63 general practitioners in 1996/97. MAIN OUTCOME MEASURES: The patients were examined and interviewed for risk factors and pharmacological treatment.
RESULTS: In 1994/95, 18% of the patients had been prescribed a lipid-lowering agent as opposed to 55% in the later survey. Consequently, the average level of LDL cholesterol in the 1996/97 population was 19% lower than in the 1994/95 population (3.8 mmol/l vs 4.7 mmol/l), which may imply a marked risk reduction. Aspirin and beta-blockers were prescribed to approximately 50% of the patients in both surveys. Diabetic patients had the same drug prescription rate and lipid profile as non-diabetics. In both surveys, about 25% of the patients were smokers.
CONCLUSION: Secondary prevention in the majority of patients with atherosclerotic disease though ameliorating is still unsatisfactory. More attention is needed to achieve and sustain treatment goals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11205092     DOI: 10.1080/028134300448805

Source DB:  PubMed          Journal:  Scand J Prim Health Care        ISSN: 0281-3432            Impact factor:   2.581


  4 in total

1.  Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?

Authors:  Lara Monesi; Fausto Avanzini; Simona Barlera; Vittorio Caimi; Davide Lauri; Paolo Longoni; Daria Roccatagliata; Massimo Tombesi; Gianni Tognoni; Maria Carla Roncaglioni
Journal:  Eur J Clin Pharmacol       Date:  2005-07-15       Impact factor: 2.953

2.  Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromso study 2001.

Authors:  Ingeborg Hartz; Anne Elise Eggen; Sameline Grimsgaard; Frode Skjold; Inger Njølstad
Journal:  Eur J Clin Pharmacol       Date:  2004-09-29       Impact factor: 2.953

3.  The SPHERE Study. Secondary prevention of heart disease in general practice: protocol of a randomised controlled trial of tailored practice and patient care plans with parallel qualitative, economic and policy analyses. [ISRCTN24081411].

Authors:  Andrew W Murphy; Margaret E Cupples; Susan M Smith; Molly Byrne; Claire Leathem; Mary C Byrne
Journal:  Curr Control Trials Cardiovasc Med       Date:  2005-07-29

4.  Sex Differences in Cardiovascular Medication Prescription in Primary Care: A Systematic Review and Meta-Analysis.

Authors:  Min Zhao; Mark Woodward; Ilonca Vaartjes; Elizabeth R C Millett; Kerstin Klipstein-Grobusch; Karice Hyun; Cheryl Carcel; Sanne A E Peters
Journal:  J Am Heart Assoc       Date:  2020-05-20       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.